三阴性乳腺癌组织中FGFR1蛋白水平及Ki67表达与微血管密度的关系分析

doi:10.3969/j.issn.1003-9198.2021.08.011

实用老年医学 ›› 2021, Vol. 35 ›› Issue (8): 833-836.doi: 10.3969/j.issn.1003-9198.2021.08.011

三阴性乳腺癌组织中FGFR1蛋白水平及Ki67表达与微血管密度的关系分析

徐超, 韩正祥, 周雷, 孙波

221001 江苏省徐州市,徐州医科大学附属医院肿瘤科

收稿日期:2021-01-04 出版日期:2021-08-20 发布日期:2021-08-30
通讯作者: 韩正祥,Email:cnhzxyg@163.com

Relationship of FGFR1 protein level and Ki67 expression with microvessel density in triple negative breast cancer tissue

XU Chao, HAN Zheng-xiang, ZHOU Lei, SUN Bo

Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221001, China

Received:2021-01-04 Online:2021-08-20 Published:2021-08-30

摘要/Abstract

摘要： 目的探究三阴性乳腺癌 (TNBC)组织中成纤维细胞生长因子受体1(FGFR1)蛋白水平及增殖细胞的相关抗原Ki67表达与微血管密度(MVD)的关系。方法以2018年5月至2019年3月在我院进行诊断并治疗的140例乳腺癌病人作为研究对象,其中TNBC病人100例(TNBC组),非TNBC病人40例(非TNBC组)。比较2组病人的FGFR1、Ki67表达水平及MVD,分析不同病理状态TNBC组病人的FGFR1、Ki67、MVD水平的差异,分析FGFR1蛋白水平及Ki67表达与MVD的关系。结果 TNBC组病人的FGFR1、Ki67表达水平显著高于非TNBC组(P<0.01);不同肿瘤大小、TNM分期、淋巴转移的TNBC病人FGFR1、Ki67、MVD水平差异均有统计学意义(P＜0.05);相关性分析显示,TNBC病人的肿瘤大小、TNM分期、淋巴转移、MVD水平与FGFR1、Ki67表达水平均呈正相关(P＜0.05)。结论 TNBC组织中FGFR1、Ki67表达与MVD呈现显著相关性,未来可通过对病人的FGFR1、Ki67进行联合检测,进一步对病情进展进行分析。

关键词: 成纤维细胞生长因子受体1, Ki67, 微血管密度, 三阴性乳腺癌

Abstract: Objective To explore the relationship of fibroblast growth factor receptor-1(FGFR1) protein level and Ki67 expression with microvessel density(MVD) in triple negative breast cancer (TNBC) tissue. Methods A total of 140 breast cancer patients diagnosed and treated in our hospital from May 2018 to March 2019 were enrolled, including 100 cases of TNBC patients(TNBC group) and 40 cases of non-TNBC patients (non-TNBC group). The expression levels of FGFR1, Ki67 and MVD in the two groups were compared, and the relationship of FGFR1 protein level and Ki67 expression with MVD in the TNBC patients with different pathological states was analyzed. Results The expression levels of FGFR1 and Ki67 in TNBC group were significantly higher than those in non-TNBC group (P<0.01). There were significance differences in the expression levels of GFR1, Ki67, MVD between the TNBC patients with different tumor size, TNM stage, lymphatic metastasis and MVD level (P＜0.05). Correlation analysis showed that the tumor size, TNM stage, lymph node metastasis and MVD level were all positively correlated with the expression levels of GFR1 and Ki67 (P＜0.05). Conclusions The expressions of FGFR1 and Ki67 in TNBC tissue are significantly correlated with MVD. In the future, FGFR1 and Ki67 can be used to analyze the disease progression.

Key words: fibroblast growth factor receptor-1, Ki67, microvessel density, triple negative breast cancer

中图分类号:

R 737.9

徐超, 韩正祥, 周雷, 孙波. 三阴性乳腺癌组织中FGFR1蛋白水平及Ki67表达与微血管密度的关系分析[J]. 实用老年医学, 2021, 35(8): 833-836.

XU Chao, HAN Zheng-xiang, ZHOU Lei, SUN Bo. Relationship of FGFR1 protein level and Ki67 expression with microvessel density in triple negative breast cancer tissue[J]. Practical Geriatrics, 2021, 35(8): 833-836.

参考文献

[1] QIN T, XU X D, ZHANG Z L,et al.Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer[J].Nanotechnology,2020,31(36): 365101.
[2] DENG H, TAN S W, GAO X Q, et al.Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity[J]. Acta Pharm Sin B,2020,10(2): 358-373.
[3] 聂琰,谭博.Hepsin、MMP-7、CD147与三阴性乳腺癌微血管密度的相关性分析[J]. 国际检验医学杂志,2020,41(15): 1863-1867.
[4] 袁野,史文杰,卓睿, 等.三阴性乳腺癌发生及预后相关基因的筛选及功能分析[J]. 广西医学,2020,42(10): 1252-1256.
[5] RIGO I Z, RØKKUM M. Predictors of outcome after primary flexor tendon repair in zone 1, 2 and 3[J]. J Hand Surg Eur Vol,2016,41(8): 793-801.
[6] PÉREZ-GARCÍAJ, SOBERINO J, RACCA F, et al.Atezolizumab in the treatment of metastatic triple-negative breast cancer[J].Expert Opin Biol Ther,2020,20(9): 981-989.
[7] ESKILER G G, SAHIN E, OZKAN A D, et al. Curcumin induces DNA damage by mediating homologous recombination mechanism in triple negative breast cancer[J].Nutr Cancer,2020,72(6): 1057-1066.
[8] KHALI D, ALSALE H.Hypereosinophilic syndrome posttreatment with triple-negative breast cancer[J]. J Appl Hematol,2020,11(2): 80-83.
[9] CHILEWSKI S D, BHOSALE D, DEES S, et al. Development of CAPER peptides for the treatment of triple negative breast cancer[J]. Cell Cycle, 2020,19(4): 432-447.
[10] DEES C, PONTIGGIA L, JASMIN J, et al.Phosphorylated STAT3 (Tyr705) as a biomarker of response to pimozide treatment in triple-negative breast cancer[J].Cancer Biol Ther,2020,21(6): 506-521.
[11] ZHAO J,HUANG J.Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1[J]. Chin Med J: Engl, 2020,133(7): 853-862.
[12] CAI D M, ZHANG X, CHEN W H.A master regulator of cholesterol biosynthesis constitutes a therapeutic liability of triple negative breast cancer[J].Mol Cell Oncol,2020,7(2):1-3.
[13] ZURLO G, ZHANG Q.Adenylosuccinate lyase hydroxylation contributes to triple negative breast cancer via the activation of cMYC[J].Mol Cel Oncol,2020,7(2):75-77.
[14] 王宇航, 孙姗姗, 梁孝栓, 等. FGFR1基因单核苷酸多态性与中国北方汉族女性乳腺癌发病风险及临床病理特征的关系[J].现代肿瘤医学,2018,26(18): 2866-2871.

三阴性乳腺癌组织中FGFR1蛋白水平及Ki67表达与微血管密度的关系分析

Relationship of FGFR1 protein level and Ki67 expression with microvessel density in triple negative breast cancer tissue

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

Metrics

推荐阅读 10